ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 25/06/2024 BST 5-day change 1st Jan Change
64.19 USD +2.18% Intraday chart for ANI Pharmaceuticals, Inc. +5.68% +16.41%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Top Midday Gainers MT
Sector Update: Health Care Stocks Advance Premarket Monday MT
Sector Update: Health Care MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Amid Uncertainty Ahead of Key Inflation Data MT
Transcript : Alimera Sciences, Inc., ANI Pharmaceuticals, Inc. - M&A Call
Top Premarket Gainers MT
ANI Pharmaceuticals to Acquire Alimera Sciences in $381 Million Deal MT
ANI Pharmaceuticals, Inc. signed a definitive agreement to acquire Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,817,663, According to a Recent SEC Filing MT
Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing MT
ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing MT
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing MT
ANI Pharmaceuticals Launches Kionex Suspension MT
ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing MT
ANI Pharmaceuticals Seeks M&A CI
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Transcript : ANI Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 10, 2024
ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance MT
Futures Rebound Pre-Bell Ahead of Earnings, Next Week's Inflation Reports; Asia, Europe Gain MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue Range $520M - $542M MT
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $4.26 - $4.67 MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q1 Revenue $137.4M, vs. Street Est of $126M MT
Chart ANI Pharmaceuticals, Inc.
More charts
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
64.19 USD
Average target price
81.6 USD
Spread / Average Target
+27.12%
Consensus
  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. News ANI Pharmaceuticals, Inc.
  5. Capital One Initiates ANI Pharmaceuticals at Overweight Rating